TP53 and endometrial endometrioid carcinoma: In endometrioid endometrial carcinoma, loss of ASRGL1 expression was an independent biomarker for disease-specific survival, and combined ASRGL1 and p53 could be used as an independent predictor of survival (Edqvist et al., 2015; Huvila et al., 2018).